educating healthcare professionals and advancing public policy for the Alpha-1 Community.” 
|
Be the First to know
sign up for our TWITTER
| Home | |
| A1AA Donation Shoppe | |
| Mission Statement | |
| What is Alpha-1 | |
| Need Help Now ! | |
|
Informational Resources
| |
| Alpha-1 Vets | |
| Health Tips | |
| FAQs | |
| Lending Library | |
| Caregivers | |
| Membership | |
| Management Team | |
|
A1AA Published Archive
| |
| Press Room | |
| Our Partners and Links | |
| Alpha-1 Advocacy Summary | |
|
in the Alpha Community  |
|
Simply click HERE provides AAT Deficiency Testing. This AAT Deficiency Testing is a COMPLETE CONFIDENCIAL TESTING SERVICE and WITHOUT COST TO YOU. Please read the detail at: AAT Deficiency Detection Center |
Eur J Cardiothorac Surg 2008;34:1191-1197. doi:10.1016/j.ejcts.2008.07.052
Copyright © 2008, European Association for Cardio-thoracic Surgery.
Published by Elsevier. All rights reserved.
Redo lung transplantation for acute and chronic lung allograft failure: long-term follow-up in a single center Satoru Osakia, James D. Maloneya, Keith C. Meyerb, Richard D. Cornwellb, Niloo M. Edwardsa, Nilto C. De Oliveiraa,* a Division of Cardiothoracic Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI, United States
b Section of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, WI, United States Received 13 May 2008; received in revised form 17 July 2008; accepted 21 July 2008.
* Corresponding author. Address: Division of Cardiovascular Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, H4/348 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-3236, United States. Tel.: +1 608 263 6311; fax: +1 608 263 0547.
Objective: This study was undertaken to evaluate outcomes of redo lung transplantation (LT) for acute and chronic graft failure. Methods: Between 1988 and 2007, 388 LT procedures were performed on 369 patients. From those, 17 (4.6%) patients had redo LT once and 2 patients had redo LT twice. Patient survival and recurrence of bronchiolitis obliterans syndrome (BOS) after redo LT were reviewed. Results: The overall survival rates of the 17 redo LT recipients at 1, 2 and 5 years were 59 ± 23%, 59 ± 23% and 42 ± 25%, respectively. For the chronic graft failure group (n = 12), survival rates at 1, 2 and 5 years were 67 ± 26%, 67 ± 26% and 44 ± 30%, respectively. These survival rates were significantly lower than the survival rates observed in our experience after primary LT (n = 352, 1-, 2- and 5-year survival rates of 88 ± 4%, 80 ± 4% and 65 ± 5%, respectively. For the acute graft failure group (n = 5), the 1-year survival rate was 40%; two patients remain free from BOS. Two patients had a second redo LT, one died from multi-organ failure on postoperative day 86 and the other died from pulmonary aspergillosis on postoperative day 214. Conclusions: Redo LT is a valid therapeutic option for selected patients with BOS and might be an option for highly selected patients with acute lung graft failure. Outcomes from a second redo LT are poor, and a second lung retransplantation must be used very cautiously, if at all.
Disclaimer: All images, quotes, material are copyrighted by their original owners and are used in this website/newsletter strictly for the purpose of information and education; and absolutely no financial profit, reproduced in complete compliance with US Code, Title 17 Copyrights, Chapter 1, Sec. 107 on Fair Usage.
L king for More Information...
| Need Help Now! Click Here |
Return Home | Back to Education Resources | Back to Informational Resources
Telephone: 540-948-6777 or 1-866-FOR-A1AA (1-866-367-2122) Fax # 540-948-6763
Copyright © 2009 Alpha-1 Advocacy Alliance, All Rights Reserved
Home | Disclaimer | Privacy Policy